Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ANVS

Annovis Bio (ANVS)

Annovis Bio Inc

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ANVS

1 2 3 4 5 6 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
29/04/2024	16h10	GlobeNewswire Inc.	Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease	NYSE:ANVS	Annovis Bio Inc
02/04/2024	13h30	GlobeNewswire Inc.	Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	NYSE:ANVS	Annovis Bio Inc
28/02/2024	13h08	IH Market News	US Stock Movers Before Market: Beyond Meat, eBay, First Solar, Urban Outfitters…	NYSE:ANVS	Annovis Bio Inc
12/02/2024	20h00	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NYSE:ANVS	Annovis Bio Inc
01/02/2024	22h05	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NYSE:ANVS	Annovis Bio Inc
22/11/2023	22h27	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NYSE:ANVS	Annovis Bio Inc
22/11/2023	22h24	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NYSE:ANVS	Annovis Bio Inc
22/11/2023	22h21	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NYSE:ANVS	Annovis Bio Inc
22/11/2023	22h14	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NYSE:ANVS	Annovis Bio Inc
21/11/2023	20h33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ANVS	Annovis Bio Inc
21/11/2023	20h31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ANVS	Annovis Bio Inc
21/11/2023	20h29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ANVS	Annovis Bio Inc
21/11/2023	20h27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ANVS	Annovis Bio Inc
08/11/2023	22h45	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:ANVS	Annovis Bio Inc
02/11/2023	12h30	Business Wire	Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients	NYSE:ANVS	Annovis Bio Inc
01/11/2023	17h28	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ANVS	Annovis Bio Inc
01/11/2023	17h24	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:ANVS	Annovis Bio Inc
31/10/2023	13h00	Business Wire	Annovis Bio Announces Pricing of $7.5 Million Public Offering	NYSE:ANVS	Annovis Bio Inc
30/10/2023	22h27	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:ANVS	Annovis Bio Inc
30/10/2023	22h17	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ANVS	Annovis Bio Inc
30/10/2023	21h48	Business Wire	Annovis Bio Announces Launch of Proposed Public Offering	NYSE:ANVS	Annovis Bio Inc
30/10/2023	21h42	Business Wire	Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)	NYSE:ANVS	Annovis Bio Inc
24/10/2023	15h13	Business Wire	Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference	NYSE:ANVS	Annovis Bio Inc
21/09/2023	15h35	GlobeNewswire Inc.	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference	NYSE:ANVS	Annovis Bio Inc
15/08/2023	13h20	Business Wire	Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update	NYSE:ANVS	Annovis Bio Inc
14/08/2023	22h40	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:ANVS	Annovis Bio Inc
18/07/2023	14h18	Business Wire	Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference	NYSE:ANVS	Annovis Bio Inc
27/06/2023	13h30	Business Wire	Annovis Bio Announces the Filing of a Groundbreaking Patent	NYSE:ANVS	Annovis Bio Inc
20/06/2023	18h05	Business Wire	Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)	NYSE:ANVS	Annovis Bio Inc
16/06/2023	22h19	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ANVS	Annovis Bio Inc

Showing the most relevant articles for your search:NYSE:ANVS

1 2 3 4 5 6 Next >>

Euro vs US Dollar

Invesco QQQ Trust Series 1

Financial Select Sector

BNP Paribas (QX)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen